## Tammy Moser Havener

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4604024/publications.pdf

Version: 2024-02-01

933447 888059 19 310 10 17 citations g-index h-index papers 21 21 21 669 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics, 2011, 12, 1407-1415.	1.3	44
2	Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma. Journal of Medicinal Chemistry, 2019, 62, 4772-4778.	6.4	34
3	A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenetics and Genomics, 2012, 22, 796-802.	1.5	32
4	Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. Diabetes, 2018, 67, 1428-1440.	0.6	32
5	Genetic Variants in <i>HSD17B3</i> , <i>SMAD3</i> , and <i>IPO11</i> Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. Clinical Pharmacology and Therapeutics, 2018, 103, 712-721.	4.7	30
6	Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. Pharmacogenomics, 2014, 15, 137-146.	1.3	27
7	Synergistic drug combinations and machine learning for drug repurposing in chordoma. Scientific Reports, 2020, 10, 12982.	3.3	27
8	Multivariate methods and software for association mapping in doseâ€response genomeâ€wide association studies. BioData Mining, 2012, 5, 21.	4.0	17
9	A comparison of association methods for cytotoxicity mapping in pharmacogenomics. Frontiers in Genetics, 2011, 2, 86.	2.3	14
10	Identification and Replication of Loci Involved in Camptothecin-Induced Cytotoxicity Using CEPH Pedigrees. PLoS ONE, 2011, 6, e17561.	2.5	14
11	Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial. PeerJ, 2017, 5, e3187.	2.0	11
12	Evaluating the role of admixture in cancer therapy via <i>in vitro</i> drug response and multivariate genome-wide associations. Pharmacogenomics, 2015, 16, 1451-1463.	1.3	8
13	High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs. PLoS Genetics, 2021, 17, e1009732.	3.5	6
14	Synergistic Chemotherapy Drug Response Is a Genetic Trait in Lymphoblastoid Cell Lines. Frontiers in Genetics, 2019, 10, 829.	2.3	5
15	Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. Frontiers in Genetics, 2016, 7, 138.	2.3	2
16	Institutional Profile: UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. Pharmacogenomics, 2010, 11, 13-21.	1.3	1
17	Abstract LB-246: Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations. , 2015, , .		1
18	The influence of Neanderthal alleles on cytotoxic response. PeerJ, 2018, 6, e5691.	2.0	1

#	Article	IF	CITATIONS
19	Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines. Pharmacogenetics and Genomics, 2021, 31, 48-52.	1.5	0